RxDoctor Payments Data

Saul Silver, MD

Interventional Cardiology · Pittsburgh, PANPI 1770544264

Payments from drug & device makers

$8,381in general payments, 2019–2025

Across 122 payments — averaging $68.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$4K
  • Johnson & Johnson$888
  • Amgen$577
  • AstraZeneca$577
  • Impulse Dynamics (USA) Inc.$301
  • E.r. Squibb & Sons, L.L.C.$230
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$4,41299%
  • Education$411%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,381 in reported general payments places this provider in the 45th percentile of 281 interventional cardiology providers in Pennsylvania.

See all interventional cardiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$138,699
Medicare patients
716
Services billed
2,112

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban724$835,145
Repatha SureclickEvolocumab508$525,695
EntrestoSacubitril/Valsartan390$458,339
XareltoRivaroxaban262$299,735
JardianceEmpagliflozin185$228,953
FarxigaDapagliflozin Propanediol92$99,138
Bisoprolol Fumarate1,337$46,046
Praluent PenAlirocumab39$37,805
OzempicSemaglutide34$31,825
MultaqDronedarone Hcl33$31,000
Repatha SyringeEvolocumab26$27,209
BrilintaTicagrelor29$25,061
NexletolBempedoic Acid46$23,503
WegovySemaglutide17$21,553
Ezetimibe727$17,320

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$78$835,145724 claims
NovartisEntresto$185$458,339390 claims
Johnson & JohnsonXarelto$888$299,735262 claims
Boehringer IngelheimJardiance$29$228,953185 claims
AstraZenecaFarxiga, Brilinta$577$124,198121 claims
Novo NordiskOzempic, Wegovy$140$53,37851 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 281 interventional cardiology providers in Pennsylvania.

Other interventional cardiology in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →